11
Jan
2024
14:00
GMT
09:00
EST
Webinar
Cardiovascular Toxicities of Novel Cancer Drugs
-
Views:
2064
-
Likes:
10
Overview
Join Dr Kathryn Ruddy (Mayo Clinic, US), Prof Dan Lenihan (Saint Francis Healthcare System, US), Prof Joe Carver (University of Pennsylvania, US), Dr Susan Dent (Duke University, US) and Melissa Chin (MASCC Executive Director) for an insightful broadcast that delves into the intricate interplay between novel cancer drugs and their potential impact on the cardiovascular system. As breakthroughs in oncology continue to unfold, understanding and managing associated cardiovascular toxicities become paramount.
The partnership combines Radcliffe’s rapidly growing global community and expertise in delivering the most innovative virtual events, with the knowledge and experience of IC-OS’s members, to curate broadcasts that challenge current practice and have real-world patient benefits.
This broadcast is for cardiologists, haematologists, oncologists, nurse practitioners, nurses and pharmacists.
The International Cardio-Oncology Society is a committed group of professionals throughout the world who are striving to protect the cardiovascular health of all patients who are undergoing cancer therapy. By optimising the cardiac status of patients with cancer before, during and after their treatment, IC-OS is collectively improving the overall outcomes including survival and quality of life. IC-OS aims to provide the latest scientific and clinical education and research for anyone treating patients with cancer in the hopes of enhancing cardiovascular protection.
The Multinational Association of Supportive Care in Cancer (MASCC) is an international, interdisciplinary organisation dedicated to the practice, education and research of supportive care in cancer. MASCC mission is to continually improve the supportive care of people with cancer – from diagnosis through to survival or end-of-life care.
Support Statement
This is an independent activity run by the International Cardio-Oncology Society (ICOS) and co-produced in collaboration with Radcliffe Cardiology. The IC-OS has been provided support to deliver this webinar series by AstraZeneca, BMS/Pfizer Alliance, Eli Lilly and Roche through an unrestricted educational grant to cover organisational costs and has had no input into the agenda or content of this educational activity. Radcliffe Cardiology has received no industry funding.
Faculty:
Daniel Lenihan
Joe Carver
Kathryn Ruddy
Susan F Dent
This broadcast is supported by
Faculty Biographies
Daniel Lenihan
Prof Daniel Lenihan is a cardio-oncologist specialising in cardiology, heart disease and advanced heart failure, at Saint Francis Healthcare System, Cape Girardeau, US.
He is a co-Founder and Board Member of the International Cardio-Oncology Society (ICOS), which is an international professional association whose primary goal is to eliminate cardiac disease as a barrier to effective cancer therapy.
He is actively involved in patient care as the Director of the Cardio-Oncology Programme, Cardiac Rehabilitation, and the Heart Failure clinic at Saint Francis Healthcare System.
Joe Carver
Prof Joe Carver is the Bernard Fishman Clinical Professor of Medicine at the Abramson Cancer Center of the University of Pennsylvania, Philadelphia, US. He is the Chief of Staff at the Abramson Cancer Center.
He is the Director of the Thalheimer Cardio-oncology Center at the Abramson Cancer Center and his clinical practice is in the subspecialty of cardio-oncology.
Kathryn Ruddy
Dr Kathryn Ruddy is a Professor of Oncology at Mayo Clinic, Rochester, US. She co-leads the Prevention, Survivorship and Care Delivery Programme at Mayo Clinic Comprehensive Cancer Center.
Nationally, she co-chairs the Symptom Intervention Committee for the Alliance for Clinical Trials in Oncology, she serves on the NCI’s Breast Cancer Steering Committee and she is an Associate Editor for JNCI.
Dr Ruddy studies long-term and late effects of cancer treatments and how to best care for cancer survivors to enhance their quality of life and reduce symptoms.
Susan F Dent
Dr Susan F Dent is a medical oncologist and professor of medicine at the Duke University School of Medicine, Durham, US.
Dr. Dent completed her medical education at McMaster University Medical School in Hamilton, Canada. Following this, she undertook residency training in internal medicine and medical oncology at the Ottawa Hospital, University of Ottawa, Ontario, Canada. Her commitment to advancing medical knowledge led her to a postgraduate research fellowship in clinical trials at the Canadian Cancer Trials Group (CCTG) in Kingston, Ontario. Subsequently, she became a staff medical oncologist at the Northwestern Ontario Cancer Center in Thunder Bay.
Dr Dent is the associate director of breast cancer clinical research and co-director of the cardio-oncology program at Duke Health. In 2001, she specialised in the treatment of breast cancer. In 2008, Dr Dent, working with her cardiology colleagues, established a multidisciplinary cardio-oncology clinic in Ottawa; the first of its kind in Canada. In 2011, she founded the Canadian Cardiac Oncology Network (CCON), a not-for-profit organisation devoted to optimisation of cancer care for patients without compromising cardiovascular health.